Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma
Interventions: Triamcinolone injection, sub-tenon; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Diet, Hypertension, Cardiovascular Diseases, Blood Pressure
Interventions: Ready-to-eat meals; Other
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
Interventions: Exercise training; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions: standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet; Dietary Supplement
Lead sponsor: CAMC Health System; Other
Eligibility: 12 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Hypertension, Systolic, Cerebrovascular Disease
Interventions: Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg; Other
Lead sponsor: UConn Health; Other
Eligibility: 75 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Latanoprost; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions: Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group); Behavioral
Lead sponsor: Texas Southern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions: Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Frespaciguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Asthma, Hypertension, Cardiovascular Risk Factor, Insulin Resistance, Stress Disorders, Post-Traumatic, Exposure to Toxic Dust
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 12 Years to 20 Years
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo); Drug · Other
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Cataracts, Glaucoma, Myopia
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 45 Years and older
Enrollment: 7,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 5
States / cities: Baltimore, Maryland • Bethesda, Maryland • Boston, Massachusetts + 2 more

Conditions: Sleep Apnea, Hypertension, Hyperlipidemia, Coronary Artery Disease, Gastroesophageal Reflux Disease, Osteoarthritis, Diabetes
Interventions: Tri Staple Technology stapler; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Azilsartan medoxomil and chlorthalidone, Chlorthalidone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 46
States / cities: Huntsville, Alabama • Montgomery, Alabama • Buena Park, California + 43 more

Conditions: Diabetes, Hypertension
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinal Disease, Glaucoma
Interventions: Optos P200TE, Predicate Device; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Model 10642 Implantable Intravascular Catheter; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 5 more

Conditions: Hypertension, Physical Disability, Aging
Interventions: Dietary intervention; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Revere, Massachusetts

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: IW-1973, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypertension
Interventions: telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 113
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more

Conditions: Pediatric Hypertension
Interventions: NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan; Other · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 10 Years to 22 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Sturge-Weber Syndrome, Glaucoma, Ocular Hypertension
Interventions: QLS-101 ophthalmic solution, 2.0 %; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years to 19 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension, Pediatric Disorder
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 17 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia • Winston-Salem, North Carolina

Search by objective public record fields.

Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery

The Ready-to-Eat Meals for Cardiovascular Health Study

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome

Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

World Trade Center Adolescent Health Study

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Family Studies of Eye Traits

Tri Staple Technology Stapler Used in Gastric Bypass

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Real-world Aliskiren Use in Diabetic Patients

Optos P200TE Agreement and Precision Study

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

The Effect of Sodium Reduction on Blood Pressure and Physical Function in Older Adults

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

N-of-1 Trials In Children With Hypertension

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Pediatric Hypertension Registry (PHREG)